Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

Blood (2018) 132 (Supplement 1): 753.

https://doi.org/10.1182/blood-2018-99-114570

Published: 2018

Journal Articles

Monitor Antiplatelet Therapy Among Patients with Ischemic Stroke By Platelet Function Assay-200 (PFA-200)

Jianqiang Ni, MD, PhD, Jingluan Tian, MD, PhD, Qi Fang, MD, PhD, Changgeng Ruan, MD PhD, Shundong Ji, PhD

Blood (2017) 130 (Supplement 1): 4919.

https://doi.org/10.1182/blood.V130.Suppl_1.4919.4919

Published: 2017

Journal Articles

Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence

Avi Leader, MD, Ravit Zelikson-Saporta, Uri Rozovski, MD, David Pereg, MD, Pia Raanani, MD, Galia Spectre, MDPhD, Michael Lishner, MD, Doron Hermoni, MD

Blood (2015) 126 (23): 1124.

https://doi.org/10.1182/blood.V126.23.1124.1124

Published: 2015

Journal Articles

Clopidogrel Modulates LPS-Induced Systemic Inflammation Through a P2Y 12 receptor Independent Pathway

Elisabetta Liverani, PhD, Mario C Rico, MD, Alexander Tsygankov, PhD, Laurie E Kilpatrick, PhD, Satya P. Kunapuli, PhD

Blood (2013) 122 (21): 2309.

https://doi.org/10.1182/blood.V122.21.2309.2309

Published: 2013

Journal Articles

Clopidogrel, a P2Y12 Receptor Antagonist, Potentiates the Inflammatory Response in a Rat Model of Peptidoglycan Polysaccharide - Induced Arthritis,

Analia E Garcia, DMD, Sripal R Mada, PhD, Mario C Rico, MD, Raul A. De La Cadena, MD, Satya P. Kunapuli, PhD

Blood (2011) 118 (21): 3287.

https://doi.org/10.1182/blood.V118.21.3287.3287

Published: 2011

Journal Articles

Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease

Ted Wun, Charles L. Knupp, MD, Lillian E. McMahon, MD, John J. Strouse, MD, PhD, Chunmei Zhou, MS, Lori E. Heath, MS, Chuke E. Nwachuku, MA, MPH, DrPH, Joseph A. Jakubowski, PhD, Kenneth J. Winters, MD, Jeffrey S. Riesmeyer, MD

Blood (2011) 118 (21): 2127.

https://doi.org/10.1182/blood.V118.21.2127.2127

Published: 2011

Journal Articles

P2Y12 Is Involved in Cancer Metastasis,

Yanhua Wang, Yueping Sun, Ph.D, Ding Li, Ph.D, Lin Zhang, Master's, degree, Kemin Wang, Weiran Chai, Ph.D, Xinping Luo, T. Kent Gartner, PhD, Junling Liu

Blood (2011) 118 (21): 3356.

https://doi.org/10.1182/blood.V118.21.3356.3356

Published: 2011

Journal Articles

Predictors of Clinically Significant Bleeding in Patients with Aortic Stenosis,

Joseph L Blackshear, MD, Dong Chen, MD, PhD, Colleen S Thomas, MS

Blood (2011) 118 (21): 3315.

https://doi.org/10.1182/blood.V118.21.3315.3315

Published: 2011

Journal Articles

A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease

Ted Wun, Denis Soulieres, MD, FRCPC, MSc, Lakshmanan Krishnamurti, MD, Abdullah Kutlar, MD, Kenneth Ataga, MD, Chunmei Zhou, MS, Lori E. Heath, MS, Chuke E. Nwachuku, MA, MPH, DrPH, Joseph A. Jakubowski, PhD, Kenneth J. Winters, MD, Jeffrey S. Riesmeyer, MD

Blood (2011) 118 (21): 847.

https://doi.org/10.1182/blood.V118.21.847.847

Published: 2011

Journal Articles

Matrix Metalloproteases and PAR Activation

Athan Kuliopulos, MD, PhD

Blood (2011) 118 (21): SCI-43.

https://doi.org/10.1182/blood.V118.21.SCI-43.SCI-43

Published: 2011

Journal Articles

A Phase 1 Study of Prasugrel in Subjects with Sickle Cell Disease: Impact on Ex Vivo Platelet Reactivity

Joseph A. Jakubowski, PhD, Chunmei Zhou, MS, David S. Small, PhD, Kenneth J. Winters, MD, D. Richard Lachno, DPhil, Andrew L. Frelinger, III, PhD, Jo Howard, MB, BChir, MRCP, FRCPath, Stipo Jurcevic, MD, Christopher D. Payne, MSc

Blood (2011) 118 (21): 1053.

https://doi.org/10.1182/blood.V118.21.1053.1053

Published: 2011

Journal Articles

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty Year Review

Zaina Parvez Qureshi, PhD, MPH, John Armstrong, PhD, Charles Bennett, MD, PhD, MPP

Blood (2011) 118 (21): 2226.

https://doi.org/10.1182/blood.V118.21.2226.2226

Published: 2011

Journal Articles

The platelet P2Y 12 receptor for adenosine diphosphate: congenital and drug-induced defects

Marco Cattaneo

Blood (2011) 117 (7): 2102–2112.

https://doi.org/10.1182/blood-2010-08-263111

Published: 2011

Journal Articles

Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.

Lawrence T Goodnough, George Despotis, Peter K Smith, Jerrold Levy, MD, Robert Poston, Mary Short, Govinda Weerakkody, LeRoy Lenarz

Blood (2010) 116 (21): 1108.

https://doi.org/10.1182/blood.V116.21.1108.1108

Published: 2010

Journal Articles

Effects of Prasugrel In a Rat Model of Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion

Atsuhiro Sugidachi, PhD, Shinji Yamaguchi, PhD, Joseph A Jakubowski, PhD, Masami Hashimoto, PhD, Yoichi Niitsu, PhD

Blood (2010) 116 (21): 3317.

https://doi.org/10.1182/blood.V116.21.3317.3317

Published: 2010

Journal Articles

In Vitro Characterization of Platelet Dysfunction In Common Hematological Disorders Using the Verify Now ® Assay

Nina D’Abreo, MD, Vatsala Kirtani, MD, Jennifer L. Kujawa Eisenstein, MD, Yelda Nouri, MD, Matt Geller, MD, Harry Staszewski, MD

Blood (2010) 116 (21): 1436.

https://doi.org/10.1182/blood.V116.21.1436.1436

Published: 2010

Journal Articles

Finishing the Picture: Clopidogrel Is Indeed the Most Common Drug Associated with Thrombotic Thrombocytopenic Purpura (TTP) In FDA Databases: Its Mechanism, Laboratory Findings, Clinical Features, and Epidemiology Differ From That Associated with Ticlopidine

Charles Bennett, MD, PhD, MPP, Zaina Qureshi, PhD, MPH

Blood (2010) 116 (21): 1527.

https://doi.org/10.1182/blood.V116.21.1527.1527

Published: 2010

Journal Articles

An Old Story: Aggressive Antithrombotic Approach Reduced or Increased the Risk of Destabilization and Adverse Events: More Questions Than Answers.

Giorgio Corinaldesi, MD, PhD, Christian Corinaldesi, MD

Blood (2009) 114 (22): 4185.

https://doi.org/10.1182/blood.V114.22.4185.4185

Published: 2009

Journal Articles

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Anaadriana Zakarija, MD, Thanh Ha Luu, Hau C. Kwaan, MD, PhD, June McKoy, MD, JD, MPH, Ivy Weiss, BS, Paul Yarnold, Nicholas Bandarenko, MD, Charles L. Bennett, MD, PhD

Blood (2009) 114 (22): 892.

https://doi.org/10.1182/blood.V114.22.892.892

Published: 2009

Journal Articles

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Blood (2008) 112 (11): 2293.

https://doi.org/10.1182/blood.V112.11.2293.2293

Published: 2008

NARROW

Small Molecule Screens Identify CDK8-Inhibitors As Candidate Diamond-Blackfan Anemia Drugs

Monitor Antiplatelet Therapy Among Patients with Ischemic Stroke By Platelet Function Assay-200 (PFA-200)

Clopidogrel Treatment Is Associated with a Decrease in Cancer Incidence

Clopidogrel Modulates LPS-Induced Systemic Inflammation Through a P2Y 12 receptor Independent Pathway

Clopidogrel, a P2Y12 Receptor Antagonist, Potentiates the Inflammatory Response in a Rat Model of Peptidoglycan Polysaccharide - Induced Arthritis,

Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease

P2Y12 Is Involved in Cancer Metastasis,

Predictors of Clinically Significant Bleeding in Patients with Aortic Stenosis,

A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease

Matrix Metalloproteases and PAR Activation

A Phase 1 Study of Prasugrel in Subjects with Sickle Cell Disease: Impact on Ex Vivo Platelet Reactivity

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A Twenty Year Review

The platelet P2Y 12 receptor for adenosine diphosphate: congenital and drug-induced defects

Transfusion Requirements and Outcomes In the Cohort of Patients Undergoing Isolated CABG Treated with Prasugrel or Clopidogrel: TRITON-TIMI 38 Data Analysis.

Effects of Prasugrel In a Rat Model of Myocardial Infarction Induced by Thrombotic Coronary Artery Occlusion

In Vitro Characterization of Platelet Dysfunction In Common Hematological Disorders Using the Verify Now ® Assay

Finishing the Picture: Clopidogrel Is Indeed the Most Common Drug Associated with Thrombotic Thrombocytopenic Purpura (TTP) In FDA Databases: Its Mechanism, Laboratory Findings, Clinical Features, and Epidemiology Differ From That Associated with Ticlopidine

An Old Story: Aggressive Antithrombotic Approach Reduced or Increased the Risk of Destabilization and Adverse Events: More Questions Than Answers.

Thienopyridine-Associated Thrombotic Thrombocytopenia Purpura: Updated Antibody Results From the SERF-TTP Study.

Distinct Mechanisms of Idiopathic and Thienopyridine-Assocaited Thrombotic Thrombocytopenia Purpura: Final Results from the Surveillance, Epidemiology, and Risk Factors for Thrombotic Thrombocytopenic Purpura (SERF-TTP) Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only